| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | CANCER TARGETED TECHNOLOGY LLC | 100 DAIRY ROAD ROOM 479 FULMER HALL | PULLMAN | WA | 99164-4630 | WHITMAN | USA | R44CA257799 | Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy | 000 | 2 | NIH | 11/25/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $400,000 ) |
| | 2024 | 2024 | CANCER TARGETED TECHNOLOGY LLC | 100 DAIRY ROAD ROOM 479 FULMER HALL | PULLMAN | WA | 99164-4630 | WHITMAN | USA | R44CA290973 | Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate Cancer | 000 | 1 | NIH | 9/2/2024 | $400,000 |
| | 2024 | 2021 | CANCER TARGETED TECHNOLOGY LLC | 100 DAIRY ROAD ROOM 479 FULMER HALL | PULLMAN | WA | 99164-4630 | WHITMAN | USA | R44CA239461 | Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer | 000 | 6 | NIH | 10/11/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $999,998 ) |
| | 2022 | 2022 | CANCER TARGETED TECHNOLOGY LLC | FULMER HALL STE 479 | PULLMAN | WA | 99164-0001 | WHITMAN | USA | R44CA257799 | Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy | 001 | 2 | NIH | 8/12/2022 | $999,998 |
| | 2022 | 2021 | CANCER TARGETED TECHNOLOGY LLC | FULMER HALL STE 479 | PULLMAN | WA | 99164-0001 | WHITMAN | USA | R44CA257799 | Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy | 000 | 1 | NIH | 1/27/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,365,869 ) |
| | 2021 | 2021 | CANCER TARGETED TECHNOLOGY LLC | FULMER HALL STE 479 | PULLMAN | WA | 99164-0001 | WHITMAN | USA | R44CA239461 | Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer | 000 | 6 | NIH | 8/23/2021 | $365,867 |
| | 2021 | 2021 | CANCER TARGETED TECHNOLOGY LLC | FULMER HALL STE 479 | PULLMAN | WA | 99164-0001 | WHITMAN | USA | R44CA257799 | Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy | 000 | 1 | NIH | 9/20/2021 | $1,000,002 |
|
| Issue Date FY: 2020 ( Subtotal = $1,441,580 ) |
| | 2020 | 2020 | CANCER TARGETED TECHNOLOGY LLC | 14241 NE WOODINVILLE-DUVALL RD. #143 | WOODINVILLE | WA | 98072 | KING | USA | R44CA239461 | Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer | 000 | 5 | NIH | 6/9/2020 | $1,441,580 |
| | 2020 | 2018 | CANCER TARGETED TECHNOLOGY LLC | 14241 NE WOODINVILLE-DUVALL RD. #143 | WOODINVILLE | WA | 98072 | KING | USA | R43CA221511 | Development of a PSMA-Targeted Small-Molecule Drug Conjugate for Prostate Cancer | 000 | 1 | NIH | 4/26/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,375,908 ) |
| | 2019 | 2019 | CANCER TARGETED TECHNOLOGY LLC | 14241 NE WOODINVILLE-DUVALL RD. #143 | WOODINVILLE | WA | 98072 | KING | USA | R44CA239461 | Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer | 000 | 4 | NIH | 7/5/2019 | $1,375,908 |
| | 2019 | 2018 | CANCER TARGETED TECHNOLOGY LLC | 14241 NE WOODINVILLE-DUVALL RD. #143 | WOODINVILLE | WA | 98072 | KING | USA | R43CA221511 | Development of a PSMA-Targeted Small-Molecule Drug Conjugate for Prostate Cancer | 000 | 1 | NIH | 11/5/2018 | $0 |
| | 2019 | 2016 | CANCER TARGETED TECHNOLOGY LLC | 14241 NE WOODINVILLE-DUVALL RD. #143 | WOODINVILLE | WA | 98072 | KING | USA | R44CA192451 | Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic | 000 | 2 | NIH | 12/17/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $300,000 ) |
| | 2018 | 2018 | CANCER TARGETED TECHNOLOGY LLC | 14241 NE WOODINVILLE-DUVALL RD. #143 | WOODINVILLE | WA | 98072 | KING | USA | R43CA221511 | Development of a PSMA-Targeted Small-Molecule Drug Conjugate for Prostate Cancer | 000 | 1 | NIH | 9/19/2018 | $300,000 |
| | 2018 | 2016 | CANCER TARGETED TECHNOLOGY LLC | 14241 NE WOODINVILLE-DUVALL RD. #143 | WOODINVILLE | WA | 98072 | KING | USA | R44CA192451 | Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic | 000 | 2 | NIH | 2/26/2018 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $923,913 ) |
| | 2016 | 2016 | CANCER TARGETED TECHNOLOGY LLC | 14136 NE WOODINVILLE-DUVALL RD | WOODINVILLE | WA | 98072 | KING | USA | R44CA192451 | Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic | 001 | 2 | NIH | 2/19/2016 | $923,913 |
| | 2016 | 2015 | CANCER TARGETED TECHNOLOGY LLC | 14136 NE WOODINVILLE-DUVALL RD | WOODINVILLE | WA | 98072 | KING | USA | R44CA192451 | Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic | 000 | 1 | NIH | 2/12/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $1,076,087 ) |
| | 2015 | 2015 | CANCER TARGETED TECHNOLOGY LLC | 14136 NE WOODINVILLE-DUVALL RD | WOODINVILLE | WA | 98072 | KING | USA | R44CA192451 | Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic | 000 | 1 | NIH | 3/3/2015 | $1,076,087 |
|
| Issue Date FY: 2011 ( Subtotal = $1,145,108 ) |
| | 2011 | 2011 | CANCER TARGETED TECHNOLOGY LLC | 14136 NE WOODINVILLE-DUVALL RD | WOODINVILLE | WA | 98072 | KING | USA | R44CA153481 | DEVELOPMENT OF A NOVEL PET IMAGING AGENT FOR PROSTATE CANCER | 000 | 2 | NIH | 9/23/2011 | $1,145,108 |
|
| Issue Date FY: 2010 ( Subtotal = $307,641 ) |
| | 2010 | 2010 | CANCER TARGETED TECHNOLOGY LLC | 14136 NE WOODINVILLE-DUVALL RD | WOODINVILLE | WA | 98072 | KING | USA | R44CA153481 | DEVELOPMENT OF A NOVEL PET IMAGING AGENT FOR PROSTATE CANCER | 000 | 1 | NIH | 9/28/2010 | $307,641 |
|
|
